-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds-
-100% complete response (CR) observed in U.S. multi-center pilot trial of skin cancers at 12 weeks-
-Targeted start of U.S. multi-center pivotal trial in skin cancers by the middle of 2022-
JERUSALEM, March 28, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported full year 2021 financial results and provided a corporate update.
"We have had an incredibly productive year, where we observed a 100% complete response rate in our multi-center U.S. pilot trial of skin cancers led by Memorial Sloan Kettering, we received two Food and Drug Administration (FDA) breakthrough device designations, one in recurrent glioblastoma and one in certain skin cancers, and we completed our acquisition of Healthcare Capital Corp and became a Nasdaq listed company," noted Alpha Tau CEO Uzi Sofer. "We are now diligently working to initiate our multi-center U.S. pivotal trial by the middle of the year, and to expand our Alpha DaRT clinical trials into additional internal organs, including the prostate cancer trial that we hope to begin imminently in Israel."
Recent Corporate Highlights: